Verde Science, Inc. announced that along with some renowned research scientists it intends to study the treatment potential of a cannabis preparation (Nabiximols) in the treatment of Huntingdon's Disease as a sponsor at 2 universities in North America. The study as currently designed will be a double-blind, placebo controlled protocol with 48 subjects.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -.--% |
2021 | Verde Science : Two more UK energy suppliers stop trading on gas price hit | RE |
2018 | Verde Science, Inc. Announces Executive Changes | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 23 | |
+4.66% | 111B | |
+11.34% | 105B | |
-12.01% | 22.34B | |
-3.81% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-9.43% | 16.96B | |
+3.20% | 13.7B | |
+37.01% | 12.45B |
- Stock Market
- Equities
- VRCI Stock
- News Verde Science, Inc.
- Verde Science, Inc. Announces Plan to Study Cannabis Preparation for Treatment of Huntingdon's Disease